NASDAQ:RGC 25 September 2025 - 22 December 2025

Regencell Bioscience Holdings Limited is back on traders’ radar. On Thursday, December 4, 2025, RGC shares surged more than 20% intraday, trading in the mid‑teens after yet another volatile session in what has arguably been 2025’s most extreme stock story. Intraday data from several market trackers showed the stock changing hands around $16–17, up roughly 24–31% on the day, with the price swinging between about $13 and over $18 on volume close to 1 million shares. GuruFocus+2StockAnalysis+2

Regencell Bioscience’s journey in 2025 has been nothing short of astonishing. The company went from an obscure penny stock to a meteoric high of $83.60 within months Stockanalysis. This 820-fold increase was “far stranger” than a typical biotech breakthrough – it happened without any major scientific news or product launch Gurufocus. Instead, a perfect storm of speculative forces sent RGC into the stratosphere.

Regencell Bioscience’s Hong Kong office. The company is an early-stage biotech leveraging Traditional Chinese Medicine for neurological disorders. Founded in 2014 and listed on Nasdaq in 2021, Regencell focuses on developing natural TCM-based treatments for conditions like ADHD and autism spectrum disorder Marketbeat. It has even explored herbal COVID-19 remedies in the past, though these remain experimental Stocktitan. Importantly, RGC is pre-revenue – it has no product sales or FDA-approved drugs yet, and subsists on research funding and IPO proceeds. In the most recent financial report, the company disclosed zero revenue and a net loss of ~$1.85 million for the half-year ended Dec 2024 Sec. Full-year 2024 losses were about $4.4 million, indicating ongoing R&D and administrative costs.